Drugs News and Research

RSS

Modified sugar compound protects against world's deadliest viruses

When a team of European researchers sought to discover how a class of antiviral drugs worked, they looked in an unlikely place: the sugar dish. A new research report appearing in the Journal of Leukocyte Biology suggests that a purified and modified form of a simple sugar chain may stop fast-acting and deadly viruses, such as Ebola, Lassa, or Marburg viruses, in their tracks.

4 Nov 2010

New noninvasive technique provides low-level electrical stimulation to reduce pain

A simple, noninvasive technique providing low-level electrical stimulation of the brain produces significant pain-reducing effects in humans, reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

4 Nov 2010

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.

4 Nov 2010

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.

4 Nov 2010

Florida to drop 350 uninsured HIV/AIDS patients from drug program; Ore. and Wash. set up enrollment periods for children's insurance; Calif. gets federal grant to update Medicaid program

The Miami Herald/The Sun Sentinel: "The Florida Department of Health plans to drop about 350 uninsured HIV/AIDS patients from a federally funded program that pays for all or most of their drugs, because of a budget crisis. An additional 2,000 or more HIV-positive patients are at risk of being bumped from the program unless the state can close a $16 million shortfall in the next few months, officials said Tuesday.

4 Nov 2010

BioCurex files patent for synthetic peptide in RECAF test

BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.

4 Nov 2010

SurModics and Edge Therapeutics enter licensing agreement for drug delivery technology

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.

4 Nov 2010

Single injection of morphine to fight persistent pain reduces testosterone level: Research

A single injection of morphine to fight persistent pain in male rats is able to strongly reduce the hormone testosterone in the brain and plasma, according to a new paper published in Molecular Pain.

4 Nov 2010

GPUs in video games foster revolution in development of new life-saving drugs

Parents may frown upon video games, but the technology used in the wildly popular games is quietly fostering a revolution in speeding the development of new products and potentially life-saving drugs. That's the topic of an article in the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Pharma in Asia-Pacific region becomes more active in R&D, study finds

In recent years, pharmaceutical companies in the Asia-Pacific region have ramped up their clinical trial activity, patent challenges of brand name drugs and their development of new products, according to report released Tuesday by CMR International, a Thomson Reuters business, Reuters reports.

4 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Deloitte releases new report on innovative strategies for oncology drug development

Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion in oncology drugs while transforming the medical outlook for many cancer patients.

3 Nov 2010

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network Ltd. a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis.

3 Nov 2010

Veterans deserve best health care coverage

The nation pauses to honor its veterans on November 11 for their patriotism, love of country, and willingness to serve and sacrifice for the common good. Naturally, we want our veterans to be taken care of, especially when it comes to their health. Those who have served their country through the United States military have several options when it comes to their health care coverage.

3 Nov 2010

Health Affairs recognizes U-M leadership in implementing Value-Based Insurance Design

Value-Based Insurance Design - a concept created at the University of Michigan and incorporated in the nation's new health care reform law - is the focus of an upcoming national policy journal.

3 Nov 2010

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

EDAP TMS SA the global leader in therapeutic ultrasound, reported today successful completion of feasibility studies aimed at improving delivery of cancer drugs using a combination of ultrasound sensitive liposomes and High Intensity Focused Ultrasound (HIFU).

3 Nov 2010

Amgen outlines key recommendations for implementing approval pathway for biosimilars

Amgen Senior Vice President of Research and Development Joe Miletich, M.D., Ph.D., will urge members of a U.S. Food and Drug Administration (FDA) panel charged with implementing a pathway for biosimilars to establish approval standards that ensure patient safety and follow a science-based approach.

3 Nov 2010

Drugs News and Research

Modified sugar compound protects against world's deadliest viruses

New noninvasive technique provides low-level electrical stimulation to reduce pain

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Florida to drop 350 uninsured HIV/AIDS patients from drug program; Ore. and Wash. set up enrollment periods for children's insurance; Calif. gets federal grant to update Medicaid program

BioCurex files patent for synthetic peptide in RECAF test

SurModics and Edge Therapeutics enter licensing agreement for drug delivery technology

Single injection of morphine to fight persistent pain reduces testosterone level: Research

GPUs in video games foster revolution in development of new life-saving drugs

PolyMedix receives $488,958 grants under QTDP program

Pharma in Asia-Pacific region becomes more active in R&D, study finds

Bortezomib reduces inflammation and promotes bone healing in arthritis models

Top 10 Medical Innovations for 2011

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Deloitte releases new report on innovative strategies for oncology drug development

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Veterans deserve best health care coverage

Health Affairs recognizes U-M leadership in implementing Value-Based Insurance Design

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

Amgen outlines key recommendations for implementing approval pathway for biosimilars

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News